Back

Early symptoms and medical history of patients with transthyretin amyloidosis cardiomyopathy: Results from the multi-country OverTTuRe study

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: New perspectives in cardiology (2) - Cardiac amyloidosis (2) Infiltrative Myocardial Disease ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Professor J Gustav Smith

Sahlgrenska Academy - University of Gothenburg, Gothenburg (Sweden)

9 More presentations in this session

Presentation thumbnail
Discussant - Cardiac amyloidosis (2)
Presentation thumbnail
Right ventricular-pulmonary arterial coupling and outcomes in cardiac amyloidosis: Systematic review and meta-analysis
Doctor A. Sakalidis (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Diagnostic yield of scintigraphy in suspected cardiac amyloidosis without left ventricular hypertrophy
Doctor N. Mora Ayestaran (Pamplona, Navarra, ES)
Abstract Slides Video
Presentation thumbnail
Effectiveness and safety of edge-to-edge MItral vaLve repair in patients with significant mitraL rEgurgitatioN aNd cardIac ATTR amyloidosis: design and rationale of the MILLENNIAL trial
Doctor L. Hauptmann (Vienna, AT)
Abstract Slides Video
Presentation thumbnail
External validation of the RAISE score for the diagnosis of transthyretin-related cardiac amyloidosis in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement
Doctor A. Roldan Guerra (Cordoba, ES)
Abstract

Access the full session

Session thumbnail
New perspectives in cardiology (2) - Cardiac amyloidosis (2)

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Session
The evolving landscape of transthyretin amyloidosis
thumbnail
Congress Session
Evolving landscape in transthyretin amyloid cardiomyopathy (ATTR-CM): clinical practice and emerging treatments
thumbnail
Congress Session
Amyloid cardiomyopathy: epidemiology, diagnosis, prognostic and treatment

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources